Pharsight

Segluromet patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8080580 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Jul, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9439902 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Oct, 2030

(7 years from now)

US9308204 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Oct, 2030

(7 years from now)

Segluromet is owned by Merck Sharp Dohme.

Segluromet contains Ertugliflozin; Metformin Hydrochloride.

Segluromet has a total of 3 drug patents out of which 0 drug patents have expired.

Segluromet was authorised for market use on 19 December, 2017.

Segluromet is available in tablet;oral dosage forms.

Segluromet can be used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

The generics of Segluromet are possible to be released after 21 October, 2030.

Drug Exclusivity Drug Exclusivity Expiration
M (M) Sep 17, 2024

Drugs and Companies using ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 19 December, 2017

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage: TABLET;ORAL

More Information on Dosage

SEGLUROMET family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic